Aktis Oncology (NASDAQ:AKTS) Sets New 1-Year Low – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $17.81 and last traded at $18.09, with a volume of 118160 shares changing hands. The stock had previously closed at $19.00.

Analysts Set New Price Targets

Several brokerages recently weighed in on AKTS. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Leerink Partners began coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price objective on the stock. Bank of America began coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price on the stock. Finally, TD Cowen assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.67.

Aktis Oncology Stock Down 2.2%

Insider Activity

In other news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the purchase, the insider owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the stock in a transaction on Monday, January 12th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the acquisition, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. This represents a 12.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders acquired 6,117,776 shares of company stock valued at $110,119,968.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.